View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
April 30, 2021updated 12 Jul 2022 11:18am

Tilsotolimod combo’s trial failure leaves refractory melanoma patients in limbo

Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) versus Yervoy alone in patients with anti-programmed death protein-1 (anti-PD-1)-refractory advanced melanoma did not meet its co-primary endpoint of objective response rate (ORR).

By GlobalData

Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) versus Yervoy alone in patients with anti-programmed death protein-1 (anti-PD-1)-refractory advanced melanoma did not meet its co-primary endpoint of objective response rate (ORR).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Idera had planned to apply for accelerated approval of this combination therapy, but will now have to wait for a potentially positive overall survival (OS) signal from the trial. These topline results will undermine confidence that tilsotolimod could be a sure bet for approval in this under-resourced line of therapy within melanoma.

Melanoma can be treated with immune checkpoint inhibitors (ICIs) such as anti-PD-1 or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents. Many patients respond well, but approximately 50% of patients will progress on ICIs, leaving them with few treatment alternatives after ICI therapy. Patients with anti-PD-1-resistant melanoma have a poor prognosis and their treatment remains an unmet clinical need. Previously, tilsotolimod looked set to meet this need.

Tilsotolimod is a therapeutic oligonucleotide that binds directly to the Toll-like receptor 9 (TLR9) in immune cells to stimulate an immune cascade. Tilsotolimod is designed to work with the ICI Yervoy to synergistically turn ‘cold’ tumors ‘hot’ by illuminating cancer cells to the immune system. While the ILLUMINATE-301 trial results only showed an ORR of 8.8%, this combination has previously achieved a 22.4% ORR in the ILLUMINATE-204 Phase I/II trial and received orphan drug and fast track designation from the FDA.

Idera is well placed to stay ahead of its competitors. There are no marketed agonist oligonucleotides for any cancer indication, but Checkmate Pharmaceuticals has remained Idera’s potential main competitor for years as its candidate, vidutolimod (CMP-001), also targets TLR9 and is in late-stage clinical trials for anti-PD-1-refractory melanoma.

While Idera believes that tilsotolimod has a competitive edge, because it avoids the increased manufacturing complexity that is brought by the virus-like particle encapsulation that vidutolimod requires, GlobalData’s recent patient-based forecast assigns a higher peak year revenue to vidutolimod. According to GlobalData’s consensus analyst forecasts, tilsotolimod’s sales are expected to reach $278M by 2027 if the tilsotolimod + Yervoy combination is approved for anti-PD-1-refractory melanoma. Idera’s plan is to open discussions with regulatory authorities and identify a path forward for this therapy in second-line patients if the ILLUMINATE-301 trial produces positive OS results.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena